Navigation überspringen
Universitätsbibliothek Heidelberg

disk Markieren   Persönliche Notiz
Drucker
Andere Formate
Exportieren/Zitieren
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Mountzios, Giannis [VerfasserIn]   i
 Samantas, E. [VerfasserIn]   i
 Senghas, Karsten [VerfasserIn]   i
 Zervas, E. [VerfasserIn]   i
 Krisam, Johannes [VerfasserIn]   i
 Samitas, K. [VerfasserIn]   i
 Bozorgmehr, Farastuk [VerfasserIn]   i
 Kuon, Jonas [VerfasserIn]   i
 Agelaki, S. [VerfasserIn]   i
 Baka, S. [VerfasserIn]   i
 Athanasiadis, I. [VerfasserIn]   i
 Gaißmaier, Lena [VerfasserIn]   i
 Elshiaty, Mariam [VerfasserIn]   i
 Daniello, Lea [VerfasserIn]   i
 Christopoulou, A. [VerfasserIn]   i
 Pentheroudakis, G. [VerfasserIn]   i
 Lianos, E. [VerfasserIn]   i
 Linardou, H. [VerfasserIn]   i
 Kriegsmann, Katharina [VerfasserIn]   i
 Kosmidis, P. [VerfasserIn]   i
 El-Shafie, Rami [VerfasserIn]   i
 Kriegsmann, Mark [VerfasserIn]   i
 Psyrri, A. [VerfasserIn]   i
 Andreadis, C. [VerfasserIn]   i
 Fountzilas, E. [VerfasserIn]   i
 Heußel, Claus Peter [VerfasserIn]   i
 Herth, Felix [VerfasserIn]   i
 Winter, Hauke [VerfasserIn]   i
 Emmanouilides, C. [VerfasserIn]   i
 Oikonomopoulos, G. [VerfasserIn]   i
 Meister, Michael [VerfasserIn]   i
 Muley, Thomas [VerfasserIn]   i
 Bischoff, Helge [VerfasserIn]   i
 Saridaki, Z. [VerfasserIn]   i
 Razis, E. [VerfasserIn]   i
 Perdikouri, E. -I. [VerfasserIn]   i
 Stenzinger, Albrecht [VerfasserIn]   i
 Boukovinas, I. [VerfasserIn]   i
 Reck, M. [VerfasserIn]   i
 Syrigos, K. [VerfasserIn]   i
 Thomas, Michael [VerfasserIn]   i
 Christopoulos, Petros [VerfasserIn]   i
Titel:Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer
Verf.angabe:G. Mountzios, E. Samantas, K. Senghas, E. Zervas, J. Krisam, K. Samitas, F. Bozorgmehr, J. Kuon, S. Agelaki, S. Baka, I. Athanasiadis, L. Gaissmaier, M. Elshiaty, L. Daniello, A. Christopoulou, G. Pentheroudakis, E. Lianos, H. Linardou, K. Kriegsmann, P. Kosmidis, R. El Shafie, M. Kriegsmann, A. Psyrri, C. Andreadis, E. Fountzilas, C.-P. Heussel, F.J. Herth, H. Winter, C. Emmanouilides, G. Oikonomopoulos, M. Meister, T. Muley, H. Bischoff, Z. Saridaki, E. Razis, E.-I. Perdikouri, A. Stenzinger, I. Boukovinas, M. Reck, K. Syrigos, M. Thomas & P. Christopoulos
E-Jahr:2021
Jahr:1 September 2021
Umfang:10 S.
Fussnoten:Gesehen am 27.01.2022
Titel Quelle:Enthalten in: ESMO open
Ort Quelle:London : BMJ, 2016
Jahr Quelle:2021
Band/Heft Quelle:6(2021), 5, Artikel-ID 100254, Seite 1-10
ISSN Quelle:2059-7029
Abstract:Background - The advanced lung cancer inflammation index [ALI: body mass index × serum albumin/neutrophil-to-lymphocyte ratio (NLR)] reflects systemic host inflammation, and is easily reproducible. We hypothesized that ALI could assist guidance of non-small-cell lung cancer (NSCLC) treatment with immune checkpoint inhibitors (ICIs). - Patients and methods - This retrospective study included 672 stage IV NSCLC patients treated with programmed death-ligand 1 (PD-L1) inhibitors alone or in combination with chemotherapy in 25 centers in Greece and Germany, and a control cohort of 444 stage IV NSCLC patients treated with platinum-based chemotherapy without subsequent targeted or immunotherapy drugs. The association of clinical outcomes with biomarkers was analyzed with Cox regression models, including cross-validation by calculation of the Harrell's C-index. - Results - High ALI values (>18) were significantly associated with longer overall survival (OS) for patients receiving ICI monotherapy [hazard ratio (HR) = 0.402, P < 0.0001, n = 460], but not chemo-immunotherapy (HR = 0.624, P = 0.111, n = 212). Similar positive correlations for ALI were observed for objective response rate (36% versus 24%, P = 0.008) and time-on-treatment (HR = 0.52, P < 0.001), in case of ICI monotherapy only. In the control cohort of chemotherapy, the association between ALI and OS was weaker (HR = 0.694, P = 0.0002), and showed a significant interaction with the type of treatment (ICI monotherapy versus chemotherapy, P < 0.0001) upon combined analysis of the two cohorts. In multivariate analysis, ALI had a stronger predictive effect than NLR, PD-L1 tumor proportion score, lung immune prognostic index, and EPSILoN scores. Among patients with PD-L1 tumor proportion score ≥50% receiving first-line ICI monotherapy, a high ALI score >18 identified a subset with longer OS and time-on-treatment (median 35 and 16 months, respectively), similar to these under chemo-immunotherapy. - Conclusions - The ALI score is a powerful prognostic and predictive biomarker for patients with advanced NSCLC treated with PD-L1 inhibitors alone, but not in combination with chemotherapy. Its association with outcomes appears to be stronger than that of other widely used parameters. For PD-L1-high patients, an ALI score >18 could assist the selection of cases that do not need addition of chemotherapy.
DOI:doi:10.1016/j.esmoop.2021.100254
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1016/j.esmoop.2021.100254
 Volltext: https://www.sciencedirect.com/science/article/pii/S2059702921002167
 DOI: https://doi.org/10.1016/j.esmoop.2021.100254
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:advanced lung cancer inflammation index
 immunotherapy
 neutrophil-to-lymphocyte ratio
 non-small-cell lung cancer
 PD-L1
K10plus-PPN:1787339289
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68871535   QR-Code
zum Seitenanfang

© Universitätsbibliothek HeidelbergMailImpressum / Datenschutz   Design